Back to search

Peptide record

TPDB11380

Antibacterial Anticancer Antifungal Toxicity standard
32 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11380
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CAFPdb dbAMP
standard
No
A 32-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CAFPdb, and other sources, with an available 3D structural model.
Sequence
RRIRFRPPRLPRPRPRPWIPPRFPFPRIPGKR
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C191H307N67O33
ANDCEQHMSTYV
RP
4069.97
13.40
12
0
8
+12
4.31
-1.456
48.75
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
5500
1.35
0
Residue Composition
number
0
A
11
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
3
I
1
L
1
K
0
M
3
F
11
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 11 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 1 K: 1 M: 0 F: 3 P: 11 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
32 reviewed residue count
C191H307N67O33 sequence-only estimate (linear, free termini)
4069.97 sequence-only estimate (linear, free termini)
13.40 sequence-only estimate (linear, free termini)
+12 sequence-only estimate (linear, free termini)
4.31 sequence-only estimate (linear, free termini)
-1.456 sequence-only estimate (linear, free termini)
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
1 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 7
Evidence 2 Activity

Activity

MIC
Antibacterial
4 µM

Target

E. faecium ATCC 19434

Source & Reference

dbAMP

Other

active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATC
Evidence 3 Activity

Activity

MIC
Antibacterial
16 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP

Other

active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa
Evidence 4 Activity

Activity

MIC
Antibacterial
1 µM

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

dbAMP

Other

TCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans
Evidence 5 Activity

Activity

MIC
Antibacterial
1 µM

Target

A. baumannii ATCC 19606

Source & Reference

dbAMP

Other

19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. ma
Evidence 6 Activity

Activity

MIC
Antibacterial
2 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP

Other

23 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. a
Evidence 7 Activity

Activity

MIC
Antibacterial
0.5 µM

Target

E. agglomerans clinical isolate

Source & Reference

dbAMP

Other

0603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 8 Activity

Activity

MIC
Antibacterial
1 µM

Target

Stenotrophomonas maltophilia ATCC 13637

Source & Reference

dbAMP

Other

1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 9 Activity

Activity

MIC
Antibacterial
0.5 µM

Target

Candida albicans ATCC 90029

Source & Reference

dbAMP

Other

uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 10 Activity

Activity

MIC
Antifungal
1 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP CAFPdb

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 7
Evidence 11 Activity

Activity

MIC
Antifungal
4 µM

Target

E. faecium ATCC 19434

Source & Reference

dbAMP CAFPdb

Other

active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATC
Evidence 12 Activity

Activity

MIC
Antifungal
16 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP CAFPdb

Other

active against E. coli ATCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa
Evidence 13 Activity

Activity

MIC
Antifungal
1 µM

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

dbAMP CAFPdb

Other

TCC 25922 (MIC 1 uM), E. faecium ATCC 19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans
Evidence 14 Activity

Activity

MIC
Antifungal
1 µM

Target

A. baumannii ATCC 19606

Source & Reference

dbAMP CAFPdb

Other

19434 (MIC 4 uM), S. aureus ATCC 25923 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. ma
Evidence 15 Activity

Activity

MIC
Antifungal
2 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP CAFPdb

Other

23 (MIC 16 uM), K. pneumoniae ATCC 700603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. a
Evidence 16 Activity

Activity

MIC
Antifungal
0.5 µM

Target

E. agglomerans clinical isolate

Source & Reference

dbAMP CAFPdb

Other

0603 (MIC 1 uM), A. baumannii ATCC 19606 (MIC 1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 17 Activity

Activity

MIC
Antifungal
1 µM

Target

Stenotrophomonas maltophilia ATCC 13637

Source & Reference

dbAMP CAFPdb

Other

1 uM), P. aeruginosa ATCC 27853 (MIC 2 uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 18 Activity

Activity

MIC
Antifungal
0.5 µM

Target

Candida albicans ATCC 90029

Source & Reference

dbAMP CAFPdb

Other

uM), E. agglomerans clinical isolate (MIC 0.5 uM), S. maltophilia ATCC 13637 (MIC 1 uM), C. albicans ATCC 90029 (MIC 0.5 uM).
Evidence 19 Activity

Activity

0% Hemolysis
Toxicity
32 µM
Hemolytic Cytotoxic
0% Hemolysis | 32 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterization of Cetacean Proline-Rich Antimicrobial Peptides Displaying Activity against ESKAPE Pathogens. | Int J Mol Sci | 2020
Evidence 20 Activity

Activity

0% Killing
Toxicity
32 µM
Cytotoxic
0% Killing | 32 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Characterization of Cetacean Proline-Rich Antimicrobial Peptides Displaying Activity against ESKAPE Pathogens. | Int J Mol Sci | 2020
Evidence 21 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes:0% Hemolysis=32µM | Cytotoxicity: HaCat: 0% Killing=32µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Mol Sci. 2020 Oct 6 21(19):7367.